Sign up to receive our newsletter

OTTBD News Items

5/9/12
National Institutes of Health unveils NCATS – National Center for Advancing Translational Sciences
The NIH has launched a novel initiative titled “Discovering New Therapeutic Uses for Existing Molecules” to help match researchers with a selection of compounds from pharmaceutical industry partners including Pfizer, AstraZeneca, and Eli Lilly and Company. The National Center for Advancing Translational Sciences (NCATS) will direct researchers’ attention to a pool of more than 20 valuable compounds that have already cleared several key steps in the development process, including safety testing in humans but are no longer actively pursued by the pharmaceutical company.

For the initial pilot phase NCATS will provide up to $20 million to fund two- and three-year staged, cooperative agreement research grants for pre-clinical and clinical feasibility studies. The academic research partners will own any intellectual property they discover through the research project with the right to publish the results of their work.

For more details about this program visit "Discovering New Therapeutic Uses for Existing Molecules" or contact The UMDNJ Office of Technology Transfer and Business Development at OTTBD@umdnj.edu.

02/29/12
Biosearch Technologies Acquires Worldwide Rights to Non-FRET Probes Patents: Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, today announced that the company has acquired worldwide rights from the University of Medicine and Dentistry of New Jersey (UMDNJ) to United States Patent 6,150,097, titled "Nucleic Acid Detection Probes Having Non-FRET Fluorescence Quenching and Kits and Assays Including Such Probes," as well as counterpart patents in Australia, Canada, France, Germany, Great Britain, Italy, and Japan, that disclose and claim, inter alia, probes having quenchers and fluorophores that are not FRET pairs, as well as their use. In addition, Biosearch has acquired rights to sublicense the non-FRET probes patents to companies that may wish to commercialize current and future non-FRET probe-based products. See FULL PRESS RELEASE

12/13/11
Foundation Venture Capital Group a Model for Other Universities
Foundation Venture Capital Group (FVCG), an affiliate of the Foundation of UMDNJ/New Jersey Health Foundation, is the focus of the lead article in the most recent edition of the newsletter Technology Transfer Tactics/. The article describes how administrators at the University of Michigan decided to use money from their $7.8 billion endowment to fund start-up companies and turned to FVCG for advice. FVCG, which has become a model for other universities, works closely with Vince Smeraglia, director of UMDNJ's Office of Technology Transfer and Business Development, to invest exclusively in research at UMDNJ by funding new life science companies. The article quotes Smeraglia and FVCG president James Golubieski. The two explain the wisdom behind creating a venture capital fund using endowments and describe the risks and rewards of investing in early-stage technologies.

Material Transfers and Sales

It is now commonplace for researchers in the biomedical sciences to share research materials, particularly unique biological reagents or materials, vectors, and cell lines. Such exchanges are essential for the rapid advancement of certain areas, and it is in the best interests of the University to encourage such exchanges where appropriate.

It is now University policy that all such exchanges be covered by an appropriate Material Transfer Agreement. These Agreements provide a formal record of what has been sent from and received by the University and perform several useful functions:

How Do I Get a Material Transfer Agreement?

If you have requested materials from another University, you will probably receive a Material Transfer Agreement from that institution. These must be signed in the Office of Technology Transfer and Business Development . For the most part these are standardized agreements, and we can give you a one-day turnaround. Occasionally these come in with provisions that we find difficult, usually in the form of requiring more access to Intellectual Property than we or you would happily accept. We will negotiate these, with your input, as rapidly as possible.

Should you wish to transfer some of your own research materials to a colleague at another institution you should do under a Material Transfer Agreement. To get such an Agreement:

Sales of Materials

If you have unique Materials in quantity sufficient to release a potion without affecting your research program, you may wish to consider selling it. This is particularly attractive in cases in which the recipient organization is a commercial firm and/or the amount requested is clearly more substantial than would be required for occasional research use. In such a case, we will need to generate a sales agreement that also contains aspects of the Material Transfer Agreement (which still would need to be done) and aspects of a sales contract. Please get in touch with us if this is a possibility. We can directly participate in the sales negotiations if you wish.